283 related articles for article (PubMed ID: 32840893)
21. Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis.
Kobayashi T; Uda A; Udagawa E; Hibi T
J Crohns Colitis; 2020 Jun; 14(5):617-623. PubMed ID: 31867632
[TBL] [Abstract][Full Text] [Related]
22. Minimal risk of lymphoma and non-melanoma skin cancer despite long-term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India.
Ranjan MK; Kante B; Vuyyuru SK; Kumar P; Mundhra SK; Golla R; Sharma R; Sahni P; Das P; Makharia G; Kedia S; Ahuja V
J Gastroenterol Hepatol; 2022 Aug; 37(8):1544-1553. PubMed ID: 35501287
[TBL] [Abstract][Full Text] [Related]
23. Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients.
Caldera F; Saha S; Wald A; Garmoe CA; McCrone S; Megna B; Ley D; Reichelderfer M; Hayney MS
Dig Dis Sci; 2018 Jun; 63(6):1532-1540. PubMed ID: 29594970
[TBL] [Abstract][Full Text] [Related]
24. Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study.
Thomsen SB; Allin KH; Burisch J; Jensen CB; Hansen S; Gluud LL; Theede K; Kiszka-Kanowitz M; Nielsen AM; Jess T
United European Gastroenterol J; 2020 Feb; 8(1):68-76. PubMed ID: 32213059
[TBL] [Abstract][Full Text] [Related]
25. Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018.
Meyer A; Drouin J; Weill A; Carbonnel F; Dray-Spira R
Aliment Pharmacol Ther; 2021 Aug; 54(3):302-311. PubMed ID: 34162011
[TBL] [Abstract][Full Text] [Related]
26. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.
Mozaffari S; Abdolghaffari AH; Nikfar S; Abdollahi M
Hum Exp Toxicol; 2015 May; 34(5):445-59. PubMed ID: 25378092
[TBL] [Abstract][Full Text] [Related]
27. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease.
Akbari M; Shah S; Velayos FS; Mahadevan U; Cheifetz AS
Inflamm Bowel Dis; 2013 Jan; 19(1):15-22. PubMed ID: 22434610
[TBL] [Abstract][Full Text] [Related]
28. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease.
Moran GW; Lim AW; Bailey JL; Dubeau MF; Leung Y; Devlin SM; Novak K; Kaplan GG; Iacucci M; Seow C; Martin L; Panaccione R; Ghosh S
Aliment Pharmacol Ther; 2013 Nov; 38(9):1002-24. PubMed ID: 24099467
[TBL] [Abstract][Full Text] [Related]
29. The risk of non-melanoma skin cancer in New Zealand in inflammatory bowel disease patients treated with thiopurines.
Bahi M; Walmsley RS; Gray AR; Young D; Hobbs CE; Aluzaite K; Schultz M
J Gastroenterol Hepatol; 2018 May; 33(5):1047-1052. PubMed ID: 29105142
[TBL] [Abstract][Full Text] [Related]
30. Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment.
Kreijne JE; de Veer RC; de Boer NK; Dijkstra G; West R; Moorsel SAW; de Jong DJ; van der Woude CJ; de Vries AC;
Aliment Pharmacol Ther; 2019 Aug; 50(4):407-415. PubMed ID: 31359480
[TBL] [Abstract][Full Text] [Related]
31. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study.
González-Lama Y; Suárez C; González-Partida I; Calvo M; Matallana V; de la Revilla J; Magaz M; Bernardo C; Agudo B; Ibarrola P; Relea L; Arévalo J; Vera MI; Abreu L
J Crohns Colitis; 2016 Jan; 10(1):55-60. PubMed ID: 26520164
[TBL] [Abstract][Full Text] [Related]
32. Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
Wong DR; Coenen MJ; Vermeulen SH; Derijks LJ; van Marrewijk CJ; Klungel OH; Scheffer H; Franke B; Guchelaar HJ; de Jong DJ; Engels LG; Verbeek AL; Hooymans PM;
J Crohns Colitis; 2017 Feb; 11(2):175-184. PubMed ID: 27402913
[TBL] [Abstract][Full Text] [Related]
33. Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study.
Mamtani R; Clark AS; Scott FI; Brensinger CM; Boursi B; Chen L; Xie F; Yun H; Osterman MT; Curtis JR; Lewis JD
Arthritis Rheumatol; 2016 Oct; 68(10):2403-11. PubMed ID: 27159030
[TBL] [Abstract][Full Text] [Related]
34. Increased risk of thiopurine-related adverse events in elderly patients with IBD.
Calafat M; Mañosa M; Cañete F; Ricart E; Iglesias E; Calvo M; Rodríguez-Moranta F; Taxonera C; Nos P; Mesonero F; Martín-Arranz MD; Mínguez M; Gisbert JP; García-López S; de Francisco R; Gomollón F; Calvet X; Garcia-Planella E; Rivero M; Martínez-Cadilla J; Argüelles F; Arias L; Cimavilla M; Zabana Y; Domènech E;
Aliment Pharmacol Ther; 2019 Oct; 50(7):780-788. PubMed ID: 31429097
[TBL] [Abstract][Full Text] [Related]
35. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.
Beaugerie L; Brousse N; Bouvier AM; Colombel JF; Lémann M; Cosnes J; Hébuterne X; Cortot A; Bouhnik Y; Gendre JP; Simon T; Maynadié M; Hermine O; Faivre J; Carrat F;
Lancet; 2009 Nov; 374(9701):1617-25. PubMed ID: 19837455
[TBL] [Abstract][Full Text] [Related]
36. Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study.
Thomsen SB; Ungaro RC; Allin KH; Elmahdi R; Poulsen G; Andersson M; Colombel JF; Jess T
Aliment Pharmacol Ther; 2022 May; 55(9):1128-1138. PubMed ID: 35080036
[TBL] [Abstract][Full Text] [Related]
37. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
McKenna MR; Stobaugh DJ; Deepak P
J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
[TBL] [Abstract][Full Text] [Related]
38. Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy.
Ong DE; Kamm MA; Hartono JL; Lust M
J Gastroenterol Hepatol; 2013 Oct; 28(10):1595-9. PubMed ID: 23662928
[TBL] [Abstract][Full Text] [Related]
39. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.
Scott FI; Mamtani R; Brensinger CM; Haynes K; Chiesa-Fuxench ZC; Zhang J; Chen L; Xie F; Yun H; Osterman MT; Beukelman T; Margolis DJ; Curtis JR; Lewis JD
JAMA Dermatol; 2016 Feb; 152(2):164-72. PubMed ID: 26510126
[TBL] [Abstract][Full Text] [Related]
40. Serious Infections in Children Born to Mothers With Inflammatory Bowel Disease With In Utero Exposure to Thiopurines and Anti-Tumor Necrosis Factor.
Meyer A; Taine M; Drouin J; Weill A; Carbonnel F; Dray-Spira R
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1269-1281.e9. PubMed ID: 34298191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
